Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aytu Bioscience Inc (AYTUD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 16,669
  • Shares Outstanding, K 4,220
  • Annual Sales, $ 3,220 K
  • Annual Income, $ -22,510 K
  • 60-Month Beta 5.21
  • Price/Sales 4.98
  • Price/Cash Flow N/A
  • Price/Book 0.85
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -48.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/06/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.3400 +22.75%
on 08/28/17
4.5000 -8.89%
on 09/14/17
-0.2000 (-4.65%)
since 08/25/17
3-Month
3.3400 +22.75%
on 08/28/17
12.0000 -65.83%
on 07/28/17
-7.6000 (-64.96%)
since 06/27/17
52-Week
3.3400 +22.75%
on 08/28/17
77.8000 -94.73%
on 10/04/16
-62.9000 (-93.88%)
since 09/27/16

Most Recent Stories

More News
Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical...

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment

Interim Results Demonstrated Preservation of Sperm Parameters After Six Months of Treatment with Nasally-Administered Natesto Testosterone Gel

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels

Natesto ''MY-T study'' - First Study to Demonstrate Improvement of Low T Symptoms in Men After Switching to Natesto from Topical Testosterone Gels

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences

Datato be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating theEffect of Natesto Nasal Testosterone on Male Fertility Parameters

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Announces ZolpiMist (TM) Global Distribution Agreement with SUDA Pharmaceuticals

Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Announces ZolpiMist(TM) Global Distribution Agreement with SUDA Pharmaceuticals

Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update

Live Conference Call and Webcast Scheduled for February 7, 2019, at 9:00 a.m. ET

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR

Tuzistra XR Enters the $3 Billion Cough and Cold Market, with 30-35 Million Prescriptions Written Annually

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)
Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program

Natesto Total Prescriptions Increased 27% and Refill Prescriptions Increased 52% Sequentially

AYTUD : 4.1000 (+3.80%)
AYTU : 1.83 (-8.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AYTUD with:

Key Turning Points

2nd Resistance Point 4.2200
1st Resistance Point 4.1600
Last Price 4.1000
1st Support Level 4.0200
2nd Support Level 3.9400

See More

52-Week High 77.8000
Fibonacci 61.8% 49.3563
Fibonacci 50% 40.5700
Fibonacci 38.2% 31.7837
Last Price 4.1000
52-Week Low 3.3400

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar